Factors associated with HPV vaccine uptake in teenage girls: A systematic review

Vaccine

Volumn 30, Issue 24, 2012, Pages 3546-3556

  Kessels, Sharon J M ^a,b   Marshall, Helen S ^a,c,d   Watson, Maureen ^e   Braunack Mayer, Annette J ^a   Reuzel, Rob ^b   Tooher, Rebecca L ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e SA Health   (Australia)

Author keywords

Adolescent health; Health behaviour; Human papillomavirus; Immunization; Systematic review; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; AFRICAN AMERICAN; ARTICLE; ATTITUDE; CHILDHOOD; CINAHL; DRUG PROGRAM; EMBASE; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; KNOWLEDGE; MEDLINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; UNITED STATES; VACCINATION;

ADOLESCENT; CHILD; DRUG UTILIZATION; ETHNIC GROUPS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84861009348     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.063     Document Type: Article

References (69)

1. Gunther O.P., Ogilvie G., Naus M., Young E., Patrick D.M., Dobson S., et al. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?. Journal of Infectious Diseases 2008, 197(12):1653-1661.
2. Garland S.M., Smith J.S. Human papillomavirus vaccines: current status and future prospects. Drugs 2010, 70(9):1079-1098.
3. Pomfret T.C., Gagnon J.M., Gilchrist A.T. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. Journal of Clinical Pharmacy and Therapeutics 2011, 36(1):1-9.
4. Bonanni P., Boccalini S., Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009, 27(Suppl. 1):A46-A53.
5. Bonanni P., Levi M., Latham N.B., Bechini A., Tiscione E., Lai P., et al. An overview on the implementation of HPV vaccination in Europe. Human Vaccines 2011, 7(Suppl.):128-135.
6. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
7. Centres for Disease Control and Prevention. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010. MMWR. Morbidity & Mortality Weekly Report 2011;60(40):1382-4.
8. Centers for Disease Control and Prevention. Available from: (27.02.12). http://www.cdc.gov/vaccines/vpd-vac/hpv/vac-faqs.htm.
9. Skinner S.R., Cooper Robbins S.C. Voluntary school-based human papillomavirus vaccination: an efficient and acceptable model for achieving high vaccine coverage in adolescents. Journal of Adolescent Health 2010, 47(3):215-218.
10. Dorleans F., Giambi C., Dematte L., Cotter S., Stefanoff P., Mereckiene J., et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. European Surveillance 2010, 15(47). pii: 19730.
11. Allen J.D., Coronado G.D., Williams R.S., Glenn B., Escoffery C., Fernandez M., et al. A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability. Vaccine 2010, 28(24):4027-4037.
12. Brewer N.T., Fazekas K.I. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Preventive Medicine 2007, 45(2):107-114.
13. Fernandez M.E., Allen J.D., Mistry R., Kahn J.A. Integrating clinical, community, and policy perspectives on human papillomavirus vaccination. Annual Review of Public Health 2010, 31:235-252.
14. Gamble H.L., Klosky J.L., Parra G.R., Randolph M.E. Factors influencing familial decision-making regarding human papillomavirus vaccination. Journal of Pediatric Psychology 2010, 35(7):704-715.
15. National Health and Medical Research Council. Available from: (27.02.12). http://www.nhmrc.gov.au/guidelines/resources-guideline-developers.
16. National Institute for health and Clinical Excellence. Available from: (27.02.12). http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/GuidelinesManual2009.jsp.
17. Centers for Disease, Control and Prevention National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2009. MMWR. Morbidity & Mortality Weekly Report 2010, 59(32):1018-1023.
18. Chun C., Velicer C., Slezak J.M., Jacobsen S.J. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clinic Proceedings 2009, 84(10):864-870.
19. Cook R.L., Zhang J., Mullins J., Kauf T., Brumback B., Steingraber H., et al. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. Journal of Adolescent Health 2010, 47(6):596-599.
20. Dempsey A., Cohn L., Dalton V., Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine 2010, 28(4):989-995.
21. Agius P.A., Pitts M.K., Smith A.M.A., Mitchell A. Human papillomavirus and cervical cancer: Gardasil vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students. Vaccine 2010, 28(27):4416-4422.
22. Ogilvie G., Anderson M., Marra F., McNeil S., Pielak K., Dawar M., et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Medicine 2010, 7(5).
23. Roberts S.A., Brabin L., Stretch R., Baxter D., Elton P., Kitchener H., et al. Human papillomavirus vaccination and social inequality: results from a prospective cohort study. Epidemiology & Infection 2011, 139(3):400-405.
24. Brewer N.T., Gottlieb S.L., Reiter P.L., McRee A.-L., Liddon N., Markowitz L., et al. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sexually Transmitted Diseases 2011, 38(3):197-204.
25. Dempsey A.F., Abraham L.M., Dalton V., Ruffin M. Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Annals of Epidemiology 2009, 19(8):531-538.
26. Gerend M.A., Weibley E., Bland H. Parental response to human papillomavirus vaccine availability: uptake and intentions. Journal of Adolescent Health 2009, 45(5):528-531.
27. Yeganeh N., Curtis D., Kuo A. Factors influencing HPV vaccination status in a Latino population; and parental attitudes towards vaccine mandates. Vaccine 2010, 28(25):4186-4191.
28. Chao C., Velicer C., Slezak J.M., Jacobsen S.J. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. American Journal of Epidemiology 2010, 171(3):357-367.
29. Rand C.M., Schaffer S.J., Humiston S.G., Albertin C.S., Shone L.P., Heintz E.V., et al. Patient-provider communication and human papillomavirus vaccine acceptance. Clinical Pediatrics 2011, 50(2):106-113.
30. Allen J.D., Othus M.K.D., Shelton R.C., Li Y., Norman N., Tom L., et al. Parental decision making about the HPV vaccine. Cancer Epidemiology Biomarkers and Prevention 2010, 19(9):2187-2198.
31. Pruitt S.L., Schootman M. Geographic disparity, area poverty, and human papillomavirus vaccination. American Journal of Preventive Medicine 2010, 38(5):525-533.
32. Reiter P.L., Cates J.R., McRee A.-L., Gottlieb S.L., Shafer A., Smith J.S., et al. Statewide HPV vaccine initiation among adolescent females in North Carolina. Sexually Transmitted Diseases 2010, 37(9):549-556.
33. McCave E.L. Influential factors in HPV vaccination uptake among providers in four states. Journal of Community Health 2010, 35(6):645-652.
34. Rouzier R., Giordanella J.-P. Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. Journal of Adolescent Health 2010, 47(3):237-241.
35. Staras S.A.S., Vadaparampil S.T., Haderxhanaj L.T., Shenkman E.A. Disparities in human papillomavirus vaccine series initiation among adolescent girls enrolled in Florida Medicaid programs: 2006-2008. Journal of Adolescent Health 2010, 47(4):381-388.
36. Rondy M., van Lier A., van de Kassteele J., Rust L., de Melker H. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine 2010, 28(9):2070-2075.
37. Caskey R., Lindau S.T., Alexander G.C. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. Journal of Adolescent Health 2009, 45(5):453-462.
38. Rosenthal S.L., Rupp R., Zimet G.D., Meza H.M., Loza M.L., Short M.B., et al. Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes. Journal of Adolescent Health 2008, 43(3):239-245.
39. Mathur M.B., Mathur V.S., Reichling D.B. Participation in the decision to become vaccinated against human papillomavirus by California High School girls and the predictors of vaccine status. Journal of Pediatric Health Care 2010, 24(1):14-24.
40. Cates J.R., Shafer A., Carpentier F.D., Reiter P.L., Brewer N.T., McRee A., et al. How parents hear about human papillomavirus vaccine: implications for uptake. Journal of Adolescent Health 2010, 47(3):305-308.
41. Brabin L., Roberts S.A., Stretch R., Baxter D., Elton P., Kitchener H., et al. A survey of adolescent experiences of human papillomavirus vaccination in the Manchester study. British Journal of Cancer 2009, 101(9):1502-1504.
42. Stretch R., Roberts S.A., McCann R., Baxter D., Chambers G., Kitchener H., et al. Parental attitudes and information needs in an adolescent HPV vaccination programme. British Journal of Cancer 2008, 99(11):1908-1911.
43. Chao C., Slezak J.M., Coleman K.J., Jacobsen S.J. Papanicolaou screening behavior in mothers and human papillomavirus vaccine uptake in adolescent girls. American Journal of Public Health 2009, 99(6):1137-1142.
44. Neubrand T.P.L., Breitkopf C.R., Rupp R., Breitkopf D., Rosenthal S.L. Factors associated with completion of the human papillomavirus vaccine series. Clinical Pediatrics 2009, 48(9):966-969.
45. Widdice L.E., Bernstein D.I., Leonard A.C., Marsolo K.A., Kahn J.A. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics 2011, 127(1):77-84.
46. Katz I.T., Ware N.C., Gray G., Haberer J.E., Mellins C.A., Bangsberg D.R. Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence. Sexual Health 2010, 7(3):279-286.
47. Galarce E.M., Minsky S., Viswanath K. Socioeconomic status: demographics, beliefs and A(H1N1) vaccine uptake in the United States. Vaccine 2011, 29(32):5284-5289.
48. Jain N., Hennessey K. Hepatitis B vaccination coverage among U.S. adolescents: National Immunization Survey-Teen, 2006. Journal of Adolescent Health 2009, 44(6):561-567.
49. Liao Q., Cowling B.J., Lam W.W., Fielding R. Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong Kong: a longitudinal study. PLoS ONE 2011, 6(3):e17713.
50. Vandermeulen C., Roelants M., Theeten H., Depoorter A.M., Van Damme P., Hoppenbrouwers K. Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants. Pediatrics 2008, 121(3):e428-e434.
51. Wallace L.A., Bramley J.C., Ahmed S., Duff R., Hutchinson S.J., Carman W.F., et al. Determinants of universal adolescent hepatitis B vaccine uptake. Archives of Disease in Childhood 2004, 89(11):1041-1042.
52. Kahn J.A., Kahn L.D.R.S. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstetrics & Gynecology 2007, 110(3):713.
53. McDougall J.A., Madeleine M.M., Daling J.R., Li C.I. Racial and ethnic disparities in cervical cancer incidence rates in the United States: 1992-2003. Cancer Causes & Control 2007, 18(10):1175-1186.
54. Downs L.S., Smith J.S., Scarinci I., Flowers L., Parham G. The disparity of cervical cancer in diverse populations. Gynecologic Oncology 2008, 109(2 Suppl):S22-S30.
55. Garnett G.P., Kim J.J., French K., Goldie S.J. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(Suppl. 3). p. S3/178-86.
56. Koulova A., Tsui J., Irwin K., Van Damme P., Biellik R., Aguado M.T. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries: June 2006-January 2008. Vaccine 2008, 26(51):6529-6541.
57. Brotherton J., Gertig D.M., Chappell G., Rowlands L., Saville M. Catching up with the catch-up: HPV vaccination coverage data for Australia women aged 18-26 years from the National HPV vaccination program register. CDI 2011, 35(2):197-201.
58. Australian Government Department of Health and Ageing. The National HPV Program Register. Available from: (21.11.11). http://health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv%23figure1.
59. Sabidó M., Gavaldà L., Olona N., Ramon J.M. Timing of hepatitis B vaccination: its effect on vaccine response in health care workers. Vaccine 2007, 25(43):7568-7572.
60. Fazekas K.I., Brewer N.T., Smith J.S. HPV vaccine acceptability in a rural Southern area. Journal of Women's Health 2008, 17(4):539-548.
61. Lazcano-Ponce E., Rivera L., Arillo-Santillán E., Salmerón J., Hernández-Avila M., Muñoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca: Mexico. Archives of Medical Research 2001, 32(3):243-247.
62. Woodhall S.C., Lehtinen M., Verho T., Huhtala H., Hokkanen M., Kosunen E. Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland. Journal of Adolescent Health 2007, 40(5):466-469.
63. Immunise Australia program. Available from: (21.2.12). http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv.
64. Centers for Disease Control and Prevention National and state vaccination coverage among adolescents aged 13 through 17 years-United States: 2010. MMWR. Morbidity & Mortality Weekly Report 2011, 60(33):1117-1123.
65. European Cervical Cancer Association. HPV vaccination across Europe. Available from: (29.02.12). http://www.ecca.info/fileadmin/user_upload/HPV_Vaccination/ECCA_HPV_Vaccination_April_2009.pdf.
66. Hughes J., Cates J.R., Liddon N., Smith J.S., Gottlieb S.L., Brewer N.T. Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiology Biomarkers and Prevention 2009, 18(2):363-372.
67. Reiter P.L., Brewer N.T., Gottlieb S.L., McRee A., Smith J.S. Parents' health beliefs and HPV vaccination of their adolescent daughters. Social Science & Medicine 2009, 69(3):475-480.
68. Reiter P.L., McRee A.L., Gottlieb S.L., Brewer N.T. Correlates of receiving recommended adolescent vaccines among adolescent females in North Carolina. Human Vaccines 2011, 7(1):67-73.
69. Brabin L., Roberts S.A., Stretch R., Baxter D., Chambers G., Kitchener H., et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008, 336(7652):1056-1058.